IP Library Granted Patent US 8,394,814
Granted Patent B2
US 8,394,814 · App. 12/586,850 · Granted Mar 12, 2013

Method of purifying crude noscapine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,394,814
App. No.
12/586,850
Granted
Mar 12, 2013
Kind
B2
Abstract

The invention provides a method for separating noscapine from an opium source without substantially changing the color of the noscapine.

Claims (26)

1. A method for separating noscapine from an opium source comprising at least one impurity that undergoes an irreversible color change when exposed to a pH of less than about 5, the method comprising:

(a) contacting the opium source with a first solvent that substantially causes the dissolution of noscapine to form a reaction mixture comprising a pH of greater than about 5; and,

(b) contacting the reaction mixture with a second solvent that reduces the solubility of the noscapine in the reaction mixture without substantially changing the solubility of the impurity such that the noscapine recrystallizes thereby separating the noscapine from the impurity in a manner that does not cause an irreversible color change in the impurity.

2. The method of claim 1 , wherein the first solvent is selected from the group consisting of alkane and substituted alkane solvents, aromatic hydrocarbons, esters, ethers, ketones, and combinations thereof.

3. The method of claim 1 , wherein the first solvent is selected from the group consisting of acetonitrile, acetone, benzene, butanol, butyl acetate, t-butyl methylether, t-butyl methylketone, chlorobenzene, chloroform, chloromethane, cyclohexane, dichloromethane, dichloroethane, diethyl ether, ethyl acetate, fluorobenzene, heptane, hexanes, isobutylmethylketone, isopropyl acetate, methylethylketone, methylisobutylketone, methyltetrahydrofuran, pentyl acetate, n-propyl acetate, tetrahydrofuran, toluene, and combinations thereof; and the second solvent is selected from the group consisting of water, methanol, ethanol, isopropanol, pentanol, and combinations thereof.

4. The method of claim 1 , wherein the impurity is selected from the group consisting of papaverrubines, glaudine, epiglaudine, oreodine, and combinations thereof.

5. The method of claim 4 , wherein the papaverrubine is selected from the group consisting of papaverrubine A, papaverrubine B, papaverrubine C, papaverrubine D, papaverrubine E, papaverrubine F, papaverrubine G, epipapaverrubine G, papaverrubine H, and combinations thereof.

6. The method of claim 1 , wherein the opium source comprises at least one other impurity selected from the group consisting of morphine, oripavine, papaverine, thebaine, codeine, codeine, cryptopine, noscapine analog, narcotoline, nor-noscapine, and combinations thereof.

7. The method of claim 1 , wherein the opium source is selected from the group consisting of poppy straw, concentrated poppy straw, opium, crude noscapine, and crude narcotine.

8. The method of claim 1 , wherein the noscapine crystals remain a tan color before and after separation from the opium source.

9. The method of claim 1 , wherein the concentration of noscapine in the reaction mixture in step (a) ranges between about 10% to about 90% of the solubility limit of noscapine in the first solvent; and the amount of the second solvent contacted with the reaction mixture is sufficient to reduce the solubility of the noscapine in the reaction mixture by a factor of at least about 10% or less of the solubility of the reaction mixture before contacting the second solvent.

10. The method of claim 1 , wherein step (a) of the method is conducted at a temperature ranging between about 50° C. and the boiling point of the first solvent, and step (b) is conducted at a temperature ranging between about 20° C. and the eutectic temperature of the combined first solvent and second solvent from step (b).

11. The method of claim 1 , wherein the second solvent is miscible with the first solvent.

12. The method of claim 1 , wherein the method further comprises:

(a) filtering the crystallized noscapine; and,

(b) rinsing the filtered noscapine product with a rinse solvent.

13. The method of claim 12 , wherein the rinse solvent is a mixture of water and a second rinse solvent selected from the group consisting of methanol, ethanol, isopropanol, pentanol, acetonitrile, acetone, and combinations thereof.

14. A method for separating noscapine from an opium source comprising at least one impurity that undergoes an irreversible color change when exposed to a pH of less than about 5, the method comprising:

(a) contacting the opium source with a first solvent selected from the group consisting of acetone, acetonitrile, and combinations thereof to form a reaction mixture having a pH of greater than about 5; and,

(b) contacting the reaction mixture with water such that the noscapine recrystallizes thereby separating the noscapine from the impurity.

15. The method of claim 14 , wherein step (a) of the method is conducted at a temperature ranging between about 40° C. and about 60° C.; step (b) is conducted at a temperature of between about 0° C. and about 25° C.; the concentration of noscapine in the reaction mixture in step (a) ranges between about 10% and about 20% by weight; and the amount of water added to the reaction mixture in step (b) is essentially equal to the volume of the first solvent in the reaction mixture.

16. The method of claim 14 , wherein the opium source is concentrated poppy straw.

17. The method of claim 14 , wherein the method further comprises filtering the reaction mixture from step (b).

18. The method of claim 14 , wherein the impurity is selected from the group consisting of papaverrubines, glaudine, epiglaudine, oreodine, and combinations thereof.

19. The method of claim 14 , wherein the opium source further comprises at least one other impurity selected from the group comprising morphine, oripavine, papaverine, thebaine, codeine, codeine, cryptopine, noscapine analog, narcotoline, nor-noscapine, and combinations thereof.

20. The method of claim 14 , wherein the noscapine crystals comprise a purity of at least 98% noscapine by weight; and noscapine crystals comprise a yield of at least 80% of the noscapine by weight of the opium source.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2009
From: MARSHALL, BENJAMIN M.; TOMAZI, KEITH G.
To: MALLINCKRODT INC.
Reel/Frame 023395/0258 →